


**FIGURE 1**


Subjective Drug Effects Scale: Liking This Feeling  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



Treatment: •-•-• NTX placebo    o-o-o 0.25 mg NTX    o-o-o 0.50 mg NTX


**FIGURE 2**

Subjective Drug Effects Scale: Liking This Feeling  
Area Under the Curve for Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means




**FIGURE 3**

Subjective Drug Effects Scale: Good Effects  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means




**FIGURE 4**

Subjective Drug Effects Scale: Good Effects  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Interaction



**FIGURE 5**


Subjective Drug Effects Scale: Feeling Sick  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



Treatment: ●-●-● NTX placebo ○-○-○ 0.25 mg NTX ○-○-○ 0.50 mg NTX


**FIGURE 6**

Subjective Drug Effects Scale: Feeling Sick  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means




**FIGURE 7**

Subjective Drug Effects Scale: Bad Effects  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
treatment-by-Period Means



**FIGURE 8**

Subjective Drug Effects Scale: Bad Effects  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



Treatment: ●-●-● NTX Placebo ●-●-● 50 mg NTX



**FIGURE 9**

Subjective Symptom Rating Scale: Antagonist  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means





FIGURE 10


Subjective Symptom Rating Scale: Antagonist  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



Treatment: ●---● NTX Placebo ○---○ 0.5 mg NTX


FIGURE 11

Pupil Diameter (mm)  
Maximum Change from Baseline (PDmax)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



**FIGURE 12**

Pupil Diameter (mm)  
Area Under the Curve for Change from Baseline (AUC)  
Population: Valid for Pharmacodynamic  
Treatment-by-Period Means



Treatment: ●---● NTX Placebo ○---○ 25 mg NTX ○---○ 50 mg NTX

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**